Report on US and Europe Pharma and Biotech Cro Market Research by Service Type, by Phase, by Indication 9 Based on Indication, by End User Forecast to 2032

Description

List of Tables

Report on US and Europe Pharma and Biotech Cro Market Research by Service Type (Clinical Development Services, Formulation Development Services, Pharmacovigilance Services, Laboratory Services, Consulting Services, Data Management Services, and Others), by Phase {Based on phase, the US and Europe Pharma and Biotech CRO Market has been segmented into Phase I, Phase II, Phase III, Phase IV. and Post Marketing Studies (PMS)}, by Indication 9 Based on Indication, the US and Europe Pharma and Biotech CRO Market has been segmented into cardiovascular, oncology, dermatology, gynecology, neurology, respiratory diseases, orthopedics, ophthalmology and others), by End User (Pharmaceutical Companies, and Biopharmaceutical Companies) Forecast to 2032

Overview of the Market

Over the course of the research period, the US and European Pharma and Biotech Cro Market is expected to grow at a robust CAGR of 10.32%.

By offering outsourced services including drug development, clinical trials, regulatory affairs, and more, CROs (Contract Research Organizations) are crucial to the biotechnology and pharmaceutical sectors. These consist of post-market surveillance, clinical trials, regulatory affairs, and medication development. By overseeing all facets of clinical trials, including design and protocol development, patient recruiting, data collecting, and analysis, CROs contribute to the simplification of the drug development process.

The main factors propelling the growth of the US and European pharmaceutical and biotech CRO markets are the pharmaceutical and biotechnology industries' increased investments in research and development, the adoption of cutting-edge technologies like artificial intelligence, big data analytics, and precision medicine, and the rise in clinical trials and studies, which creates a demand for CRO services for trial management and support. However, it is anticipated that the fierce competition among CROs as well as worries about data security and privacy will impede the expansion of the worldwide market. However, there are plenty of development prospects in emerging nations, and the market is expected to benefit greatly from the rising investment in precision and personalized medicine.

Market Segmentation

Clinical development services, formulation development services, pharmacovigilance services, laboratory services, consulting services, data management services, and other services, including regulatory affairs services, are the different service types that make up the US and European Pharma and Biotech CRO Market.

The market has been divided into several phases, including Post Marketing Studies (PMS), Phase I, Phase II, Phase III, and Phase IV.

The market has been divided into several segments based on indications, including respiratory disorders, orthopedics, ophthalmology, neurology, dermatology, gynecology, cardiovascular, and cancer.

The US and European Pharma and Biotech CRO Market has been divided into pharmaceutical and biopharmaceutical companies based on the end user.

The market has been divided into the US and Europe based on country and area.

Key Players

KLIF, FGK Clinical Research, Ergomed Group, Astrum CRO, Optimapharm, Kapadi, TFS HealthScience, Winicker Norimed GmbH, JSB Solutions Srl, and IQVIA Holding, Inc. are some of the major industry participants.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING RESEARCH AND DEVELOPMENT INVESTMENTS BY PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES
- 4.2.2 GROWING ADOPTION OF CUTTING-EDGE TECHNOLOGY SUCH AS ARTIFICIAL INTELLIGENCE, BIG DATA ANALYTICS, AND PRECISION MEDICINE
- 4.2.3 INCREASED NUMBER OF CLINICAL TRIALS AND STUDIES GENERATES DEMAND FOR CRO SERVICES FOR TRIAL MANAGEMENT AND SUPPORT
4.3 RESTRAINTS
- 4.3.1 HIGH COST OF PHOTODYNAMIC THERAPY EQUIPMENT AND PROCEDURES
4.4 OPPORTUNITY
- 4.4.1 GROWING INVESTMENT IN PERSONALIZED AND PRECISION MEDICINE

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE US & EUROPE PHARMA AND BIOTECH CRO MARKET
5.3 LIST OF CONTRACT RESEARCH ORGANIZATION BY EUROPE/EUROPE COUNTRIES OFFERING SERVICES TO PHARMACEUTICAL AND BIOPHARMACEUTICAL

6 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE

6.1 OVERVIEW
6.2 CLINICAL DEVELOPMENT SERVICES
6.3 FORMULATION DEVELOPMENT SERVICES
6.4 PHARMACOVIGILANCE SERVICES
6.5 LABORATORY SERVICES
6.6 CONSULTING SERVICES
6.7 DATA MANAGEMENT SERVICES
6.8 OTHERS

7 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY PHASE

7.1 OVERVIEW
7.2 PHASE I
7.3 PHASE II
7.4 PHASE III
7.5 PHASE IV
7.6 POST MARKETING STUDIES (PMS)

8 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY INDICATION

8.1 OVERVIEW
8.2 CARDIOVASCULAR
8.3 ONCOLOGY
8.4 DERMATOLOGY
8.5 GYNAECOLOGY
8.6 NEUROLOGY
8.7 RESPIRATORY DISEASES
8.8 ORTHOPAEDICS
8.9 OPHTHALMOLOGY
8.10 OTHERS

9 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY END USER

9.1 OVERVIEW
9.2 PHARMACEUTICAL COMPANIES
9.3 BIOPHARMACEUTICAL COMPANIES

10 US & EUROPE PHARMA AND BIOTECH CRO MARKET, BY REGION

10.1 OVERVIEW
10.2 US
10.3 EUROPE
10.4 EASTERN EUROPE
- 10.4.1 POLAND
- 10.4.2 ROMANIA
- 10.4.3 BULGARIA
- 10.4.4 BELARUS
- 10.4.5 GEORGIA
- 10.4.6 LATVIA
- 10.4.7 LITHUANIA
- 10.4.8 REST OF EASTERN EUROPE
10.5 WESTERN EUROPE
- 10.5.1 GERMANY
- 10.5.2 FRANCE
- 10.5.3 UK
- 10.5.4 SPAIN
- 10.5.5 SWITZERLAND
- 10.5.6 NETHERLANDS
- 10.5.7 REST OF WESTERN EUROPE
10.6 NORTHERN EUROPE
- 10.6.1 DENMARK
- 10.6.2 SWEDEN
- 10.6.3 NORWAY
- 10.6.4 ICELAND
- 10.6.5 FINLAND
- 10.6.6 IRELAND
- 10.6.7 REST OF NORTHERN EUROPE
10.7 SOUTHERN EUROPE
- 10.7.1 GREECE
- 10.7.2 PORTUGAL
- 10.7.3 CROATIA
- 10.7.4 REST OF SOUTHERN EUROPE
10.8 CENTRAL EUROPE
- 10.8.1 HUNGARY
- 10.8.2 SLOVAKIA
- 10.8.3 CZECH REPUBLIC
- 10.8.4 AUSTRIA
- 10.8.5 REST OF CENTRAL EUROPE

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2023
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 AQUISITION
- 11.6.2 FACILITY LAUNCH
- 11.6.3 INVESTMENT
- 11.6.4 EXPANSION

12 COMPANY PROFILES

12.1 KLIFO
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 SERVICE OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 KEY STRATEGIES
12.2 OPTIMAPHARM
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 SERVICES OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
12.3 FGK CLINICAL RESEARCH GMBH
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 SERVICE OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 KEY STRATEGIES
12.4 ERGOMED GROUP
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 SERVICE OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
12.5 ASTRUM/ PHARMALOG
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 SERVICE OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
12.6 KAPADI
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 SERVICES OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
12.7 TFS HEALTHSCIENCE
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 SERVICES OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
12.8 WINICKER NORIMED GMBH
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 SERVICES OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 JSB SOLUTIONS SRL
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 SERVICES OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 IQVIA HOLDING, INC
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 SERVICES OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 SWOT ANALYSIS
- 12.10.6 KEY STRATEGIES

13 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 LIST OF CONTRACT RESEARCH ORGANIZATION BY EUROPE/EUROPE COUNTRIES OFFERING SERVICES TO PHARMACEUTICAL AND BIOPHARMACEUTICAL
TABLE 3 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 4 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR CLINICAL DEVELOPMENT SERVICES, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 5 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR FORMULATION DEVELOPMENT SERVICES, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 6 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHARMACOVIGILANCE SERVICES, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 7 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR LABORATORY SERVICES, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 8 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR CONSULTING SERVICES, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 9 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR DATA MANAGEMENT SERVICES, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 10 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR OTHERS, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 11 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 12 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE I, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 13 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE II, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 14 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE III, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 15 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE IV, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 16 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR POST MARKETING STUDIES (PMS), BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 17 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 18 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR CARDIOVASCULAR, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 19 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR ONCOLOGY, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 20 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR DERMATOLOGY, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 21 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR GYNAECOLOGY, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 22 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR NEUROLOGY, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 23 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 24 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR ORTHOPAEDICS, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 25 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR OPHTHALMOLOGY, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 26 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR OTHERS, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 27 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 28 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 29 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR BIOPHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2019-2032 (USD MILLION)
TABLE 30 US & EUROPE PHARMA AND BIOTECH CRO MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 31 US: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 32 US: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 33 US: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 34 US: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 35 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 36 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 37 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 38 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 39 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 40 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 41 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 42 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 43 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 44 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 45 POLAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 46 POLAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 47 POLAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 48 POLAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 49 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 50 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 51 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 52 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 53 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 54 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 55 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 56 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 57 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 58 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 59 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 60 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 61 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 62 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 63 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 64 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 65 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 66 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 67 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 68 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 69 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 70 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 71 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 72 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 73 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 74 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD BILLION)
TABLE 75 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 76 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 77 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 78 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 79 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 80 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 81 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 82 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 83 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 84 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 85 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 86 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 87 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 88 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 89 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 90 UK: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 91 UK: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 92 UK: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 93 UK: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 94 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 95 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 96 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 97 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 98 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 99 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 100 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 101 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 102 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 103 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 104 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 105 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 106 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 107 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 108 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 109 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 110 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 111 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 112 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 113 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 114 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 115 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 116 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 117 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 118 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 119 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 120 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 121 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 122 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 123 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 124 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 125 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 126 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 127 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 128 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 129 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 130 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 131 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 132 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 133 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 134 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 135 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 136 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 137 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 138 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 139 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 140 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 141 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 142 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 143 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 144 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 145 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 146 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 147 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 148 GREECE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 149 GREECE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 150 GREECE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 151 GREECE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 152 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 153 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 154 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 155 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 156 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 157 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 158 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 159 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 160 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 161 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 162 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 163 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 164 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 165 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 166 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 167 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 168 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 169 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 170 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 171 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 172 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 173 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 174 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 175 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 176 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 177 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 178 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 179 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 180 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 181 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 182 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 183 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 184 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 185 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION)
TABLE 186 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019-2032 (USD MILLION)
TABLE 187 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 188 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019-2032 (USD MILLION)
TABLE 189 AQUISITION
TABLE 190 FACILITY LAUNCH
TABLE 191 INVESTMENT
TABLE 192 EXPANSION
TABLE 193 KLIFO: SERVICES OFFERED
TABLE 194 KLIFO: KEY DEVELOPMENTS
TABLE 195 OPTIMAPHARM: SERVICES OFFERED
TABLE 196 OPTIMAPHARM: KEY DEVELOPMENTS
TABLE 197 FGK CLINICAL RESEARCH: SERVICES OFFERED
TABLE 198 FGK CLINICAL RESEARCH: KEY DEVELOPMENTS
TABLE 199 ERGOMED GROUP: SERVICES OFFERED
TABLE 200 ERGOMED GROUP: KEY DEVELOPMENTS
TABLE 201 ASTRUM/PHARMLOG: SERVICES OFFERED
TABLE 202 ASTRUM/PHARMLOG: SERVICES OFFERED
TABLE 203 KAPADI: SERVICES OFFERED
TABLE 204 TFS HEALTHSCIENCE: SERVICES OFFERED
TABLE 205 WINICKER NORIMED GMBH: SERVICES OFFERED
TABLE 206 JSB SOLUTIONS SRL: SERVICE OFFERED
TABLE 207 IQVIA HOLDING, INC: SERVICES OFFERED

LIST OF FIGURES

FIGURE 1 US AND EUROPE PHARMA AND BIOTECH CRO MARKET: STRUCTURE
FIGURE 2 US & EUROPE PHARMA AND BIOTECH CRO MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2019-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2029-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: US & EUROPE PHARMA AND BIOTECH CRO MARKET
FIGURE 6 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, SERVICE TYPE, 2023 & 2032 (USD MILLION)
FIGURE 7 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2023 & 2032 (USD MILLION)
FIGURE 8 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY SERVICE TYPE, 2023
FIGURE 9 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, PHASE, 2023 & 2032 (USD MILLION)
FIGURE 10 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2023 & 2032 (USD MILLION)
FIGURE 11 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY PHASE, 2023
FIGURE 12 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, INDICATION, 2023 & 2032 (USD MILLION)
FIGURE 13 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2023 & 2032 (USD MILLION)
FIGURE 14 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY INDICATION, 2023
FIGURE 15 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, END USER, 2023 & 2032 (USD MILLION)
FIGURE 16 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY END USER, 2023 & 2032 (USD MILLION)
FIGURE 17 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY END USER, 2023
FIGURE 18 US & EUROPE PHARMA AND BIOTECH CRO MARKET, BY REGION, 2023 & 2032 (USD MILLION)
FIGURE 19 US & EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 (% SHARE)
FIGURE 20 US MARKET ANALYSIS: PHARMA AND BIOTECH CRO MARKET, 2019-2032 (USD MILLION)
FIGURE 21 EUROPE MARKET ANALYSIS: PHARMA AND BIOTECH CRO MARKET, 2019-2032 (USD MILLION)
FIGURE 22 EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 & 2032 (USD MILLION)
FIGURE 23 EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 (%)
FIGURE 24 EASTERN EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 25 EASTERN EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 (%)
FIGURE 26 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 27 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 28 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 29 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 30 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 31 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 32 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 33 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 34 US AND EUROPE PHARMA AND BIOTECH CRO MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023
FIGURE 35 COMPETITOR DASHBOARD: US AND EUROPE PHARMA AND BIOTECH CRO MARKET
FIGURE 36 OPTIMAPHARM: SWOT ANALYSIS
FIGURE 37 ERGOMED GROUP: SWOT ANALYSIS
FIGURE 38 KAPADI: SWOT ANALYSIS
FIGURE 39 WINICKER NORIMED GMBH: SWOT ANALYSIS
FIGURE 40 IQVIA HOLDING, INC: SWOT ANALYSIS
FIGURE 41 IQVIA HOLDING, INC: SWOT ANALYSIS